RxDoctor Payments Data

Andrew Feldman, DO

Family Medicine · Deland, FLNPI 1780687848

Payments from drug & device makers

$423,352in general payments, 2019–2025

Across 172 payments — averaging $2461.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$111K
  • Pfizer$90K
  • Teva Pharmaceuticals USA, Inc.$67K
  • Currax Pharmaceuticals LLC$42K
  • Acrotech Biopharma Inc.$37K
  • Amgen$30K
  • plus $47K from 14 others
$297in research payments, 2019–2025

Across 1 payment — averaging $297.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$297

What the payments were for

  • Food & beverage$1,183100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$423,352 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,696
Medicare patients
157
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$56,845
EliquisApixaban50$55,350
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$33,470
XareltoRivaroxaban18$25,476
JardianceEmpagliflozin13$21,421
FarxigaDapagliflozin Propanediol12$9,577
Breo ElliptaFluticasone/Vilanterol12$4,762
Rosuvastatin Calcium315$4,746
SymbicortBudesonide/Formoterol Fumarate16$4,735
ArexvyRsvpref3 Antigen/As01e/Pf14$4,095
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,685
Gabapentin93$2,200
Testosterone17$1,921
Atorvastatin Calcium211$1,773
Albuterol Sulfate HfaAlbuterol Sulfate63$1,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$167$56,84552 claims
PfizerEliquis$89,924$55,35050 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$18,023$42,32753 claims
Boehringer IngelheimJardiance$40$21,42113 claims
AstraZenecaFarxiga, Symbicort$53$14,31228 claims
AbbVieSynthroid$212$53313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Deland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →